Oxcarbazepine in the treatment of bipolar disorder: A review

Canadian Journal of Psychiatry

Volumn 51, Issue 8, 2006, Pages 540-545

  Pratoomsri, Wetid ^a   Yatham, Lakshmi N ^a   Bond, David J ^a   Lam, Raymond W ^a   Sohn, Chang Ho ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bipolar disorder; Depression; Drug interactions; Mania; Oxcarbazepine

Indexed keywords

HALOPERIDOL; LITHIUM; OXCARBAZEPINE; VALPROIC ACID;

ATAXIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; BLURRED VISION; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY; HYPONATREMIA; INSOMNIA; MUSCLE TWITCH; NAUSEA; NEUROLOGIC DISEASE; PARESTHESIA; RASH; REVIEW; SIDE EFFECT; SKIN DEFECT; TREMOR; VERTIGO; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33746683201     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370605100809     Document Type: Review

References (48)

1. Rybakowski JK, Amsterdam JD, Dyson WL, Frazer A, Winokur A, Kurtz J. Factors contributing to erythrocyte lithium-sodium countertransport activity in lithium-treated bipolar patients. Pharmacopsychiatry 1989;22:16 -20.
2. Coryell W, Winokur G, Solomon D, Shea T, Leon A, Keller M. Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychol Med 1997;27:281-9.
3. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004;65(Suppl 10):28 -35.
4. Muller AA, Stoll KD. Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany. In: Emrich HM, editor. Anticonvulsants in affective disorders. Amsterdam (NL): Excerpta Medica; 1984. p 139- 47.
5. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004;5:627-35.
6. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003;42:1023- 42.
7. Ketter TA, Post RM. Clinical pharmacology and pharmacokinetics of carbamazepine. In: Joffee RT, editor. Anticonvulsants in mood disorders. New York (NY): Marcel Dekker; 1994. p 147-87.
8. Elwes RD, Binnie CD. Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet 1996;30:403-15.
9. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35(Suppl 3):S10 -S13.
10. White HS. Mechanism of action of newer anticonvulsants. J Clin Psychiatry 2003;64(Suppl 8):5-8.
11. Houtkooper MA, Lammertsma A, Meyer JW, Goedhart DM, Meinardi H, van Oorschot CA, and others. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia 1987;28:693-8.
12. French JA, Kanner AM, Bautista J, bou-Khalil B, Browne T, Harden CL, and others. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy; a report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-73.
13. United States Depression Guideline Panel. Depression in primary care. AHCPR Pub. No. 93 0551. Rockville(MD): US Department of Health and Human Services, Agency for Health Care Policy and Research; 1993.
14. Mark S, Bauer LM. Structured group psychotherapy for bipolar disorder: the life goals program. New York (NY): Springer; 2003.
15. Gaudino MP, Smith MJ, Matthews DT. Use of oxcarbazepine for treatment-resistant aggression. Psychiatr Serv 2003;54:1166-7.
16. Malek-Ahmadi P, Hanretta AT. Possible reduction in posttraumatic stress disorder symptoms with oxcarbazepine in a patient with bipolar disorder. Ann Pharmacother 2004;38:1852-4.
17. Teitelbaum M. Oxcarbazepine in bipolar disorder. J Am Acad Child Adolesc Psychiatry 2001;40:993-4.
18. Nasr S. Oxcarbazepine for mood disorders. Am J Psychiatry 2002;159:1793.
19. Ghaemi SN, Berv DA, Klugman J, Rosenquist KJ, Hsu DJ. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry 2003;64:943-5.
20. Nassir GS, Ko JY, Katzow JJ. Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review. Bipolar Disord 2002;4:70-4.
21. Centorrino F, Albert MJ, Berry JM, Kelleher JP, Fellman V, Line G, and others. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord 2003;5:370-4.
22. Reinstein MJ. Oxcarbazepine: review of 200 subjects treated for mania in a hospital setting. 155th Annual Meeting of the American Psychiatric Association: 2002, May 18-23; Philadelphia (PA).
23. Munasifi FA. The use of oxcarbazepine in the treatment of children, adolescents and adults with bipolar affective disorder. 5th Annual Meeting of the European College of Neuropsychopharmacology: 2002, October 5-10; Barcelona (SP).
24. Platt DE. Retrospective chart review on the use of oxcarbazepine in patients with bipolar disorder. 5th International Conference on Bipolar Disorder: 2003, June 12-14; Pittsburgh (PA).
25. Nars SJCM. Oxcarbamazepine for the treatment of bipolar disorder. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA).
26. Pratoomsri W, Yatham LN, Sohn CH, Solomons K, Lam RW. Oxcarbazepine add-on in the treatment of refractory bipolar disorder. Bipolar Disord 2005;7(Suppl 5):37-42.
27. Raja M, Azzoni A. Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders. Int J Neuropsychopharmacol 2003;6:409-14.
28. Velikonja MHK. Effect of oxcarbazepine (GP 47.680) on affective and schizoaffective symptoms: a preliminary report. In Okuma T, Emrich HM, and Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam (HL): Excerpta Medica; 1984. p. 208-10.
29. Munoz RA. Oxcarbazepine for the treatment of bipolar disorder. 155th Annual Meeting of the American Psychiatric Association: 2002 May 18-23; Philadelphia (PA).
30. Benedetti A, Lattanzi L, Pini S, Musetti L, Dell'Osso L, Cassano GB. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 2004;79:273-7.
31. Hummel B, Walden J, Stampfer R, Dittmann S, Amann B, Sterr A, and others. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord 2002;4:412-7.
32. Reinstein MJ, Sonnenberg JG, Hedberg TG, Jones LE, Reyngold P. Oxcarbazepine versus divalproex sodium for the continuing treatment of mania. Clinical Drug Investigation, 2003;23:671-7.
33. Emrich HM, Altmann H, Dose M, von Zersson D. Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacol Biochem Behav 1983;19:369-72.
34. Emrich HM, Dose M, von Zersson D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985;8:243-50.
35. Emrich HM. Studies with oxcarbazepine (trileptal) in acute mania. Int Clin Psychopharmacol 1990;5(Suppl 1):83-8.
36. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993;44:529-33.
37. Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993;34:163-5.
38. Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res 1988;2:269-71.
39. Pendlebury SC, Moses DK, Eadie MJ. Hyponatraemia during oxcarbazepine therapy. Hum Toxicol 1989;8:337-44.
40. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, and others. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993;87:224-7.
41. Zakrzewska JM, Patsalos PN. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1989;52:472-6.
42. Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001;21:904-19.
43. Bourgeois BF, D'Souza J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience. Epilepsy Behav 2005;7:375-82.
44. Hellewell JS. Oxcarbazepine (trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord 2002;72(Suppl1):S23-S34.
45. Emrich HM, Dose M, von Zerssen D. Action of sodium-valproate and of oxcarbazepine in patients with affective disorders. In Okuma T, Emrich HM, Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam (NE): Excerpta Medica; 1984. p 45-55.
46. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001;15:137-63.
47. McKee PJ, Blacklaw J, Forrest G, Gillham RA, Walker SM, Connelly D, and others. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994;37:27-32.
48. Beydoun A. Clinical use of tricyclic anticonvulsants in painful neuropathies and bipolar disorders. Epilepsy Behav 2002;3(Suppl 3):S18-S22.